Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2002 1
2003 2
2004 1
2005 6
2006 4
2007 4
2008 6
2009 6
2010 16
2011 17
2012 23
2013 16
2014 16
2015 15
2016 13
2017 21
2018 20
2019 22
2020 23
2021 21
2022 25
2023 23
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

261 results

Results by year

Filters applied: . Clear all
Page 1
Catechol-Amyloid Interactions.
Le NTK, Kang EJ, Park JH, Kang K. Le NTK, et al. Among authors: kang ej. Chembiochem. 2023 Dec 14;24(24):e202300628. doi: 10.1002/cbic.202300628. Epub 2023 Oct 31. Chembiochem. 2023. PMID: 37850717 Review.
Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04).
Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, Kim SW, Kim IH, Lee S, Kim YJ, Park JH, Park SG, Lee KH, Kang EJ, Kim JW, Shin SH, Ock CY, Nam BH, Lee J, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ. Park S, et al. Among authors: kang ej. J Clin Oncol. 2024 Apr 10;42(11):1241-1251. doi: 10.1200/JCO.23.01891. Epub 2023 Oct 20. J Clin Oncol. 2024. PMID: 37861993 Clinical Trial.
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
Cho JH, Lim SH, An HJ, Kim KH, Park KU, Kang EJ, Choi YH, Ahn MS, Lee MH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Cho JH, et al. Among authors: kang ej. J Clin Oncol. 2020 Feb 10;38(5):488-495. doi: 10.1200/JCO.19.00931. Epub 2019 Dec 11. J Clin Oncol. 2020. PMID: 31825714 Free PMC article. Clinical Trial.
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer.
Sung C, An J, Lee S, Park J, Lee KS, Kim IH, Han JY, Park YH, Kim JH, Kang EJ, Hong MH, Kim TY, Lee JC, Lee JL, Yoon S, Choi CM, Lee DH, Yoo C, Kim SW, Jeong JH, Seo S, Kim SY, Kong SY, Choi JK, Park SR. Sung C, et al. Among authors: kang ej. Nat Cancer. 2023 Jun;4(6):844-859. doi: 10.1038/s43018-023-00572-5. Epub 2023 Jun 12. Nat Cancer. 2023. PMID: 37308678
Spreading depolarizations in ischaemia after subarachnoid haemorrhage, a diagnostic phase III study.
Dreier JP, Winkler MKL, Major S, Horst V, Lublinsky S, Kola V, Lemale CL, Kang EJ, Maslarova A, Salur I, Lückl J, Platz J, Jorks D, Oliveira-Ferreira AI, Schoknecht K, Reiffurth C, Milakara D, Wiesenthal D, Hecht N, Dengler NF, Liotta A, Wolf S, Kowoll CM, Schulte AP, Santos E, Güresir E, Unterberg AW, Sarrafzadeh A, Sakowitz OW, Vatter H, Reiner M, Brinker G, Dohmen C, Shelef I, Bohner G, Scheel M, Vajkoczy P, Hartings JA, Friedman A, Martus P, Woitzik J. Dreier JP, et al. Among authors: kang ej. Brain. 2022 May 24;145(4):1264-1284. doi: 10.1093/brain/awab457. Brain. 2022. PMID: 35411920 Clinical Trial.
[CT Imaging Findings in Non-Atherosclerotic Coronary Artery Disease].
Park J, Park B, Kang EJ, Lee J. Park J, et al. Among authors: kang ej. Taehan Yongsang Uihakhoe Chi. 2022 Jan;83(1):70-83. doi: 10.3348/jksr.2021.0165. Epub 2022 Jan 21. Taehan Yongsang Uihakhoe Chi. 2022. PMID: 36237354 Free PMC article. Review. Korean.
261 results